Jardiance

Jardiance (generic name: empagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Empagliflozin acts as a blocker for the SGLT2 protein in the kidney tubules. Its primary function is to reduce the amount of glucose and sodium being reabsorbed into the blood. This ensures that glucose and salt are expelled through urine and not returned to the bloodstream. As well as the effect on glucose, Jardiance reduces the heart’s workload and decreases the internal pressure inside the kidney’s filtering units. The benefits include: An improvement in glycemic control for adults with type 2 diabetes A reduction in the risk of sustained kidney damage from high salt excretion A reduction in the risks of heart failure with reduced ejection fraction ( HFrEF) . Dosage The prescribing doctor sets the dosage based on each patient’s underlying condition. It is essential to follow the prescribing doctor’s instructions. Before use, read the manufacturer’s Product Insert that comes with the medication.